Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 See also  




2 References  













Nialamide






●العربية
 ●Español
 ●فارسی
 ●Italiano
 ●Polski
 ●Português
 ●Русский
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Suomi
 ●தமிழ்
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Nialamide
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • BR: Class C1 (Other controlled substances)[1]
    • Identifiers

    • N-benzyl-3-(N-(pyridine-4-carbonyl)hydrazino)propanamide

    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.000.073 Edit this at Wikidata
    Chemical and physical data
    FormulaC16H18N4O2
    Molar mass298.346 g·mol−1
    3D model (JSmol)

    • O=C(NNCCC(=O)NCc1ccccc1)c2ccncc2

    • InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22) checkY

    • Key:NOIIUHRQUVNIDD-UHFFFAOYSA-N checkY

      (verify)

    Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[2] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[3][4]

    Side effects include agitation and insomnia, less frequently dry mouth, dizziness, blurred vision, and hypomania, and rarely leukopenia and hepatitis. As with other MAOIs, a hypertensive crisis can be triggered by co-ingestion of tyramine. It is metabolized into isoniazid, an anti-tuberculosis agent, and so is contraindicated in patients with tuberculosis. The recommended dosage range is 75 to 200 mg per day, with maintenance doses as low as 12.5 mg every other day.[5]

    The antiatherogenic activity of nialamide was used to design pyridinolcarbamate.[6]

    See also[edit]

    References[edit]

    1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  • ^ William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
  • ^ Gad SC (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
  • ^ Shorter E (28 September 2008). Before Prozac: The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5.
  • ^ Council on Drugs (1971). AMA Drug Evaluations (Report). Chicago: American Medical Association. LCCN 75147249. Retrieved April 5, 2021.
  • ^ Bencze WL, Hess R, DeStevens G (6 December 2012). "Hypolipidemic Agents". Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Vol. 13. Springer Science & Business Media. pp. 217–92. doi:10.1007/978-3-0348-7068-9_5. ISBN 9783642661907. PMID 4982663. Retrieved 3 October 2017. {{cite book}}: |journal= ignored (help)

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Nialamide&oldid=1199548810"
    Categories: 
    ●Hepatotoxins
     ●Monoamine oxidase inhibitors
     ●4-Pyridyl compounds
     ●Hydrazides
     ●Propionamides
     ●Withdrawn drugs
     Hidden categories: 
    ●CS1 Brazilian Portuguese-language sources (pt-br)
     ●CS1 errors: periodical ignored
     ●Articles with short description
     ●Short description is different from Wikidata
     ●ECHA InfoCard ID from Wikidata
      


    ●This page was last edited on 27 January 2024, at 09:48 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki